M-M-R II SUMMARY
M-M-R II (Measles, Mumps, and Rubella Virus Vaccine Live) is a live virus vaccine for vaccination against measles (rubeola), mumps and rubella (German measles).
M-M-R II is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months of age or older.
Published Studies Related to M-M-R II (Measles / Mumps / Rubella Vaccine)
Immunologic effects of hydroxyurea in sickle cell anemia. 
maturation and vaccine responses... CONCLUSIONS: Hydroxyurea does not appear to have significant deleterious effects
Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine
using new measles and rubella working seeds in healthy children in Taiwan and
Singapore: a phase II, randomized, double-blind trial. 
seed virus stock, in Taiwanese and Singaporean children (NCT00892775)... CONCLUSION: The immune responses elicited by the MMRV(new WS) vaccine were
Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. [2009.08.13]
This open-label, randomised, controlled study examined antibody persistence following infant vaccination at 2, 3 and 4 months of age with either an acellular pertussis, diphtheria, tetanus, inactivated poliovirus, Haemophilus influenzae type b (DT(5)aP-IPV-Hib; Pediacel) or a whole-cell pertussis (DTwP//Hib+oral poliomyelitis vaccine [OPV]) combination vaccine, given concomitantly with meningococcal serogroup C conjugate (MCC) vaccine, followed by a Hib booster at approximately 15 months of age...
Reducing immunization discomfort in 4- to 6-year-old children: a randomized clinical trial. [2009.08]
OBJECTIVE: The goal was to test a multifaceted distraction method designed to reduce injection-associated pain in school-aged children... CONCLUSION: This multifaceted distraction intervention reduced significantly the pain and discomfort of childhood immunizations in children 4 to 6 years of age.
Safety of a refrigerator-stable varicella vaccine (VARIVAX) in healthy 12- to 15-month-old children: A randomized, double-blind, cross-over study. [2009.07]
The safety of a single injection of the refrigerator-stable formulation of varicella vaccine VARIVAX was assessed in a blind, randomized, cross-over trial... In summary, the refrigerator-stable formulation of VARIVAX had a good safety profile and was well tolerated in healthy children aged 12 to 15 months, consistent with experience with the frozen formulation of VARIVAX.
Clinical Trials Related to M-M-R II (Measles / Mumps / Rubella Vaccine)
Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix®) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M M R®II), in Children 12 to 15 Months of Age [Completed]
The purpose of this study is to evaluate consistency in terms of the immune response to
three different lots of GSK Biologicals' trivalent MMR vaccine manufactured to target
potencies, and compare its immunogenicity to Merck & Co., Inc.'s MMR vaccine, which is
approved for use in the United States (US).
Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age [Active, not recruiting]
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals'
trivalent MMR (Priorix®), comparing it to Merck's MMR vaccine (M-M-R®II), which is approved
for use in the US in healthy children 12 to 15 months of age.
Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age [Completed]
The purpose of this study is to compare two measles, mumps and rubella conjugate vaccines
(manufactured by GSK and Merck and Company ) in terms of the immune response elicited and
safety with a six month follow-up after first vaccination. Additionally, antibody
persistence will be assessed one and two years after administration of MMR vaccine.
The Protocol Posting has been updated following Protocol amendment 1 and 2, Oct 2009.
The Safety and Immunogenicity Study of Rotavirus Vaccine Simultaneously Vaccinated With MR or MMR Vaccine [Enrolling by invitation]
Nowadays these are some vaccines being vaccinated simultaneously, and a doubt is aroused if
the safety and immunogenicity are same between inoculating several vaccines simultaneously
and inoculating individually. So we carry out this study.
The purpose of this study is to evaluate the difference of safety and immunogenicity on
vaccinating rotavirus vaccine simultaneously with measles-rubella vaccine(MR) or
measles-mumps-rubella vaccine(MMR) compared to vaccinating rotavirus vaccine, MR or MMR
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life [Active, not recruiting]
The purpose of this study is to evaluate end of shelf-life potency in terms of the
immunogenicity and safety of GSK Biologicals' trivalent MMR vaccine, by comparing it to
Merck & Co., Inc.'s MMR vaccine, which is approved for use in the United States (US).
Page last updated: 2015-08-10